Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Ongoing monitoring of high-cost drug categories
Review top-spend therapeutic classes (GLP-1, biologics, oncology, rare disease).
Provide quarterly reports with trend insights and action steps.
Coordinate with your PBM or consultant to implement improvements.
Ongoing monitoring of high-cost drug categories
Review top-spend therapeutic classes (GLP-1, biologics, oncology, rare disease).
Provide quarterly reports with trend insights and action steps.
Coordinate with your PBM or consultant to implement improvements.